Biofourmis Connect: ‍Connecting drug development to care delivery

Biofourmis Connect offers life science partners the opportunity to accelerate drug research, make therapeutics safer and more effective, and scale digital drug companions through our tech-enabled care delivery services.

Woman sitting down at a table, looking at her laptop. Example vitals are shown.

Powered by our innovative technology platform, Biofourmis offers connected, configurable, and individualized care options, managed both virtually and in-person for patients at home. For healthcare providers and risk-bearing entities, we improve clinical, operational, and economic outcomes across the care continuum.


Woman sitting down wearing a blood pressure cuff and looking at a pill bottle.

Digital clinical trials

Our technology-enabled, scalable clinical research platform supports trial decentralization, precision participant recruitment, and equitable access to treatment options for patients everywhere*.

Our partners can:

Accelerate recruitment and raise rates of research participation through our growing global network of health system partners and sites

Ease patient burden and improve retention with digital patient engagement tools, and integrated in-home healthcare delivery and study visits

Accelerate clinical development with remote data collection and novel digital endpoints from our library of biomarkers across multiple therapeutic areas

Monitor and manage side effects, adverse events, and other safety concerns

Collect real-world evidence to inform R&D, commercial decision making, and lifecycle line extension

Digital drug companions

We help our partners develop and commercialize novel digital companion technologies that enhance traditional drug therapies, such as digital biomarkers that track pain or identify cardiac events1,2.

By studying the efficacy and expanding the use of these advances, our partners accumulate evidence and market differentiation for their products through:

Developing and integrating digital biomarkers and SaMD into established care pathways

Monitoring and management of side effects, adverse events, and other safety concerns to mitigate risk and enable patients to avoid hospital stays during therapy

Algorithm-guided recommendations for therapy titration and dose optimization based on individual’s data and baseline to drive precision medicine delivery

Digital patient engagement programs for personalized condition management and improved patient adherence

Man in sweater looking at his phone.

Market access solutions

We offer care pathway integration for approved therapies to help ensure that patients have access to the right treatment when and where they need it.

Our partners benefit from:

Patient identification through our growing network of health system partners to find therapy candidates and to drive both clinical and commercial outcomes

Integration into our disease-specific dynamic care pathways to optimize care delivery

Virtual visits and digital patient support programs to drive patient adherence to therapeutic protocols

In-home therapy administration, monitoring, and services with Biofourmis Care

Observational data and surveillance to support FDA post-market drug safety monitoring

Shaping a more healthful future

We’ve partnered with Chugai to develop digital tools that objectively measure pain to personalize care for patients with endometriosis.
Women’s health
Read More
With Vanderbilt University, we’re investigating remote monitoring and early detection of adverse events in cancer patients receiving CAR-T therapy.
Oncology treatment
Read More
AU Health selected Biofourmis to scale up a comprehensive remote care program, the first of its kind in Georgia.
Continuum-wide care
Read More
We partnered with Appalachian Regional Healthcare to bring care at home services to underserved rural areas.
Health equity
Read More
We partnered with nonprofit Appalachian Regional Healthcare to bring hospital at home services to underserved rural areas.
Health equity
Read More
Augusta University Health selected us to scale up a continuum-wide, comprehensive  remote care program, the first and only of its kind in Georgia.
Continuum-wide care
Read More
We’re participating in a study on optimizing medication therapy for chronic cardiovascular conditions, particularly in populations with a history of healthcare disparities.
Cardiovascular disease
Read More

Interested in learning more?

Tablet showing data from the Biofourmis platform.
proof points for

Scale and precision

Just as we carefully gather and track biomarker data on every patient, we also study the results our partners have achieved using our technology.


global clinical trial results our partners have achieved using our technology


countries with clinical trial participants


increase in usage and dosage optimization of heart failure medication3

Patient experience for

Access and engagement

Biofourmis patients typically report a 98+% level of satisfaction with our services3. The opportunity to participate in trials and manage their medications from home helps deliver a better patient experience. Our goal is to improve their quality of life in even more ways:

Icon of headphones


Without geographic and economic barriers, a more diverse patient pool can take part in clinical trials and receive the care they need

Icon of people with medical cross on chest


Remote patient management helps maintain protocol adherence and identify clinical deviations, improving patient experience and safety

Icon of messages


Virtual visits from health and wellness professionals along with coordinated digital patient experience programs offer timely education and guidance on the patient’s specific condition

Icon of clock


Reduced travel costs and time to clinics and trial sites for patients and caregivers

Icon of phone with notification


Increased patient engagement via daily personal care plans, progress tracking, and ongoing patient-specific education

3. Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction, Akshay S. Desai, MD1,2; Taylor Maclean, MS1; Alexander J. Blood, MD1,2; et al,, JAMA Cardiol. 2020;5(12):1430-1434. doi:10.1001/jamacardio.2020.3757.
4. Biofourmis data on file.

*Subject to geography and connectivity